The effect of tamoxifen therapy on serum apolipoprotein A-I level is modified by the apolipoprotein E phenotype
- 1 March 2001
- journal article
- other
- Published by Elsevier in Clinical Biochemistry
- Vol. 34 (2) , 161
- https://doi.org/10.1016/s0009-9120(01)00197-7
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapyClinical Biochemistry, 2000
- Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteinsAtherosclerosis, 1999
- Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapyAtherosclerosis, 1995
- Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol.Journal of Lipid Research, 1994
- Long term effects of tamoxifen on blood lipid values in breast cancer.BMJ, 1992
- Regulation of hepatic apolipoprotein synthesis in the 17 alpha-ethinyl estradiol-treated rat.Journal of Lipid Research, 1991
- Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine.Journal of Lipid Research, 1989
- Apolipoprotein E polymorphism and atherosclerosis.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988